What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres.
Antimicrobial stewardship
Antimicrobials use
COVID-19
Multidrug resistant organisms
SARS-CoV-2
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
29 08 2022
29 08 2022
Historique:
received:
19
04
2022
accepted:
22
08
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
1
9
2022
Statut:
epublish
Résumé
Discontinuation of antimicrobial stewardship programs (ASPs) and increased antibiotic use were described during SARS-CoV-2 pandemic. In order to measure COVID-19 impact on ASPs in a setting of high multidrug resistance organisms (MDRO) prevalence, a qualitative survey was designed. In July 2021, eighteen ID Units were asked to answer a questionnaire about their hospital characteristics, ASPs implementation status before the pandemic and impact of SARS-CoV-2 pandemic on ASPs after the 1st and 2nd pandemic waves in Italy. Nine ID centres (50%) reported a reduction of ASPs and in 7 cases (38.9%) these were suspended. After the early pandemic waves, the proportion of centres that restarted their ASPs was higher among the ID centres where antimicrobial stewardship was formally identified as a priority objective (9/11, 82%, vs 2/7, 28%). SARS-CoV-2 pandemic had a severe impact in ASPs in a region highly affected by COVID-19 and antimicrobial resistance but weaknesses related to the pre-existent ASPs might have played a role.
Identifiants
pubmed: 36038903
doi: 10.1186/s13756-022-01152-5
pii: 10.1186/s13756-022-01152-5
pmc: PMC9421115
doi:
Types de publication
Letter
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Investigateurs
Andrea Giacomelli
(A)
Marianna Rossi
(M)
Raffaele Bruno
(R)
Silvia Garilli
(S)
Ripa Marco
(R)
Liana Signorini
(L)
Francesca Bai
(F)
Angelo Pan
(A)
Marco Merli
(M)
Davide Ricaboni
(D)
Chiara Molteni
(C)
Simone Vasilij Benatti
(SV)
Barbara Castiglioni
(B)
Cristina Rovelli
(C)
Manuela Piazza
(M)
Marco Franzetti
(M)
Informations de copyright
© 2022. The Author(s).
Références
Antibiotics (Basel). 2021 Aug 31;10(9):
pubmed: 34572638
Antimicrob Resist Infect Control. 2021 Oct 21;10(1):151
pubmed: 34674756
Antimicrob Resist Infect Control. 2020 Sep 22;9(1):154
pubmed: 32962759
Antibiotics (Basel). 2021 Jan 23;10(2):
pubmed: 33498716
MMWR Morb Mortal Wkly Rep. 2020 Dec 04;69(48):1827-1831
pubmed: 33270611
J Hosp Infect. 2020 Sep;106(1):198-199
pubmed: 32425287
Antimicrob Resist Infect Control. 2021 Feb 3;10(1):28
pubmed: 33536077
Clin Microbiol Infect. 2019 Jan;25(1):20-25
pubmed: 29625170
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88
pubmed: 32703320
Antibiotics (Basel). 2021 Nov 16;10(11):
pubmed: 34827343
J Antimicrob Chemother. 2021 Oct 11;76(11):3045-3058
pubmed: 34473285
Clin Microbiol Infect. 2021 Apr;27(4):520-531
pubmed: 33418017